Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGOBSERVATIONAL

Prediction of Drug Response in Gastric Cancer Based on 3D Bioprinting

Research on the Value of Predicting Drug Efficacy Based on 3D Bioprinting for Constructing In Vitro Gastric Cancer Models

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

The therapeutic regimens for adjuvant and neoadjuvant chemotherapy in gastric cancer (GC) predominantly hinge on clinical experience. Consequently, there is an imperative need for preclinical models to facilitate the guidance of individualized medicine. The investigators plan to establish three-dimensional (3D) bioprinted GC models derived from surgically resected tumor tissues of GC patients. These in vitro 3D models will be subjected to treatment with the identical chemotherapy drugs administered to the corresponding patients from whom the models are sourced. The sensitivity of the chemotherapy drugs will be assayed within the in vitro models, and the actual response to chemotherapy in patients will be meticulously evaluated. This observational study aims to substantiate the potential utility of 3D bioprinted tumor models in prognosticating the response to chemotherapy in GC.

Who May Be Eligible (Plain English)

Who May Qualify: - More than 18 years old - Patients previously diagnosed with gastric cancer or confirmed by pathology as having gastric cancer postoperatively. - Patients who have undergone preoperative imaging examinations, including plain and contrast-enhanced CT scans of the chest, abdomen, and pelvis, as well as gastric MRI for tumor staging, and who are planned for preoperative (neo)adjuvant therapy after multidisciplinary team (MDT) discussion; patients with advanced gastric cancer who are confirmed by postoperative pathology to require (neo)adjuvant therapy. - The patient or their family members are able to comprehend the research protocol and are willing to participate in this study, providing written willing to sign a consent form. Who Should NOT Join This Trial: - History of other malignancies or serious medical conditions - Inability to provide independent willing to sign a consent form Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * More than 18 years old * Patients previously diagnosed with gastric cancer or confirmed by pathology as having gastric cancer postoperatively. * Patients who have undergone preoperative imaging examinations, including plain and contrast-enhanced CT scans of the chest, abdomen, and pelvis, as well as gastric MRI for tumor staging, and who are planned for preoperative (neo)adjuvant therapy after multidisciplinary team (MDT) discussion; patients with advanced gastric cancer who are confirmed by postoperative pathology to require (neo)adjuvant therapy. * The patient or their family members are able to comprehend the research protocol and are willing to participate in this study, providing written informed consent. Exclusion Criteria: * History of other malignancies or serious medical conditions * Inability to provide independent informed consent

Treatments Being Tested

PROCEDURE

surgical resection

Surgical resection will be performed for locoregional lesions .

OTHER

Adjuvant chemotherapy

Regimens of adjuvant chemotherapy are directed by clinical guidance and experience.

OTHER

neoadjuvant therapy

Regimens of neoadjuvant chemotherapy are directed by clinicalguidance and experience

Locations (1)

Peking Union Medical College Hospital
Beijing, Beijing Municipality, China